Dr. Melillo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2554 Bear Den Rd
Frederick, MD 21701Phone+1 301-639-2190
Education & Training
- University of Naples Faculty of MedicineClass of 1981
Certifications & Licensure
- MD State Medical License 2000 - 2025
Clinical Trials
- UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma Start of enrollment: 2002 Jun 01
Publications & Presentations
PubMed
- 220 citationsSafety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinica...Lillian L. Siu, Caroline Even, Ricard Mesia, Éva Remenár, Amaury Daste
JAMA Oncology. 2019-02-01 - 196 citationsDevelopment of HIF-1 inhibitors for cancer therapyBarbara Onnis, Annamaria Rapisarda, Giovanni Melillo
Journal of Cellular and Molecular Medicine. 2009-09-01 - 20 citationsA phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.Shivaani Kummar, Martin Gutierrez, Erin R. Gardner, William D. Figg, Giovanni Melillo
Cancer Chemotherapy and Pharmacology. 2010-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: